GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company says new ...
MLIP calculations successfully identify suitable dopants for a novel photocatalytic material, report researchers from the ...
Full year 2025 revenue of $71.7 million, up 40%Record full-year operating cash flow of $13.1 million, up 60%Board ...
Interesting Engineering on MSN
US: Lockheed’s new long-range missile for moving land, sea targets aces flight test
On March 12, 2026, Lockheed Martin successfully completed the first flight test of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results